March 1, 2020
Praetego will showcase their candidates as potential disease modifying drugs against serious diabetic complications, starting with Diabetic Peripheral Neuropathy, at the CED NC Venture Connect Summit. The Amadorins are novel small molecules developed by Praetego scientists and designed from a clinically proven prototype.